DEF 14A: Creative Medical Technology Holdings Seeks Stockholder Approval for Share Increase, Director Elections, and Executive Pay

Creative Medical Technology Holdings is holding its 2024 Annual Meeting of Stockholders on July 19, 2024, to vote on key proposals including increasing authorized shares, electing directors, and ratifying executive compensation.

Summary

• Creative Medical Technology Holdings is convening its Annual Meeting of Stockholders on July 19, 2024.
• Stockholders will vote on five proposals, including the election of five directors, an amendment to increase authorized common stock from 5,000,000 to 25,000,000 shares, an advisory vote on executive compensation, and the ratification of Haynie & Company as the independent registered public accountants for the fiscal year ending December 31, 2024.
• The Board of Directors recommends voting FOR all proposals.
• The record date for determining stockholders eligible to vote is June 3, 2024.
• As of the record date, there were 1,348,126 shares of Common Stock issued and outstanding.
• A Series B Preferred Stock held by the CEO has 100,000,000 votes but can only vote on the Share Increase Proposal and will be voted in the same proportion as the votes cast by shares of Common Stock on the Share Increase Proposal.
• The Series B Preferred Stock will be automatically redeemed upon approval of the Share Increase Proposal.
• The company has retained Okapi Partners LLC, a proxy solicitation firm, to solicit proxies for a fee of $8,000 plus expenses.

Sentiment

Score: 6

Explanation: The document is primarily procedural, outlining proposals for the annual meeting. While there are positive aspects like the board's engagement and ethics code, the potential for dilution and related-party transactions temper the overall sentiment.

Positives

• The Board of Directors is actively engaged in risk oversight and has established committees to address key governance areas.
• The company has a Code of Business Conduct and Ethics in place.
• The audit committee has reviewed the financial statements and recommended their inclusion in the Annual Report on Form 10-K.
• The company is taking steps to accelerate product development through the acquisition of research tools.

Negatives

• The company's compensation actually paid to Named Executive Officers is not at all correlated with total shareholder return or net income (loss).
• The proposed increase in authorized shares could have an anti-takeover effect.

Risks

• The increase in authorized shares could dilute existing stockholders' ownership.
• The company's executive compensation may not be directly aligned with shareholder returns or net income.
• The company relies on related-party transactions, which could present conflicts of interest.

Future Outlook

The company desires to have additional shares available to provide additional flexibility to use its capital stock for business and financial purposes in the future, including raising capital, providing equity incentives, establishing strategic relationships, and acquisitions.

Management Comments

• Timothy Warbington, CEO, invites stockholders to attend the Annual Meeting and emphasizes the importance of their vote.

Industry Context

As a biotechnology company, Creative Medical Technology Holdings operates in a competitive and highly regulated industry, requiring ongoing investment in research and development and adherence to cGMP standards.

Comparison to Industry Standards

• The company's executive compensation structure, including base salaries and potential bonuses, appears consistent with compensation practices at similarly sized biotechnology companies.
• The use of stock options and warrants as part of executive compensation is a common practice in the biotech industry to align management interests with shareholder value.
• The company's related-party transactions, such as the research tool purchase from Narkeshyo LLC, are subject to scrutiny and require appropriate disclosure and approval processes, similar to industry standards.

Related Party Transactions

• The company entered into a patent license agreement with Jadi Cell, LLC, a company owned and controlled by a former director, Dr. Amit Patel.
• The company acquired U.S. Patent No. 9,598,673 from its affiliate CMH, with the inventors being former directors Thomas Ichim and Amit Patel, and Annette Marleau.
• The company purchased research tools for $5,000,000 from Narkeshyo LLC, an entity a former director and current consultant is affiliated with.

Stakeholder Impact

• Approval of the share increase proposal could dilute existing shareholders' ownership.
• Executive compensation decisions impact shareholder value and company performance.
• Related-party transactions could raise concerns about conflicts of interest and fair value.

Next Steps

• Stockholders to vote on the proposals outlined in the proxy statement.
• The company to file articles of amendment with the Secretary of State of Nevada if the share increase proposal is approved.
• The Board and compensation committee to consider the results of the say-on-pay vote in future executive compensation decisions.
• The company to disclose voting results on a Current Report on Form 8-K within four business days after the Annual Meeting.

Key Dates

Keywords

proxy statement, annual meeting, stockholders, directors, executive compensation, authorized shares, Haynie & Company, corporate governance, related party transactions